PortalPublikationenEfficacy and safety of carfilzomib-based regimens in frail p...

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Standard

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. / Facon, Thierry; Niesvizky, Ruben; Mateos, Maria-Victoria; Siegel, David; Rosenbaum, Cara; Bringhen, Sara; Weisel, Katja; Ho, P Joy; Ludwig, Heinz; Kumar, Shaji; Wang, Kenneth; Obreja, Mihaela; Yang, Zhao; Klippel, Zandra; Mezzi, Khalid; Goldrick, Amanda; Tekle, Christina; Dimopoulos, Meletios A.

in: BLOOD ADV, Jahrgang 4, Nr. 21, 10.11.2020, S. 5449-5459.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Facon, T, Niesvizky, R, Mateos, M-V, Siegel, D, Rosenbaum, C, Bringhen, S, Weisel, K, Ho, PJ, Ludwig, H, Kumar, S, Wang, K, Obreja, M, Yang, Z, Klippel, Z, Mezzi, K, Goldrick, A, Tekle, C & Dimopoulos, MA 2020, 'Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma', BLOOD ADV, Jg. 4, Nr. 21, S. 5449-5459. https://doi.org/10.1182/bloodadvances.2020001965

APA

Facon, T., Niesvizky, R., Mateos, M-V., Siegel, D., Rosenbaum, C., Bringhen, S., Weisel, K., Ho, P. J., Ludwig, H., Kumar, S., Wang, K., Obreja, M., Yang, Z., Klippel, Z., Mezzi, K., Goldrick, A., Tekle, C., & Dimopoulos, M. A. (2020). Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. BLOOD ADV, 4(21), 5449-5459. https://doi.org/10.1182/bloodadvances.2020001965

Vancouver

Facon T, Niesvizky R, Mateos M-V, Siegel D, Rosenbaum C, Bringhen S et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. BLOOD ADV. 2020 Nov 10;4(21):5449-5459. https://doi.org/10.1182/bloodadvances.2020001965

Bibtex

@article{f68f1159e2fb402aa6cf3c40632bd735,
title = "Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma",
abstract = "Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance status or comorbidities. This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib [27 mg/m2]-lenalidomide-dexamethasone [KRd27] vs lenalidomide-dexamethasone [Rd]), ENDEAVOR (carfilzomib [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), and ARROW (once-weekly carfilzomib [70 mg/m2]-dexamethasone [Kd70] vs carfilzomib [27 mg/m2]-dexamethasone [Kd27]) studies. A frailty algorithm incorporating age, Charlson comorbidity index, and performance status classified patients as fit, intermediate, or frail. Results are presented for frail patients (ASPIRE, n = 196; ENDEAVOR, n = 330; ARROW, n = 141). In ASPIRE, median progression-free survival (PFS) (hazard ratio; 95% confidence interval) was 24.1 (KRd27) vs 15.9 months (Rd) (0.78; 0.54-1.12); median overall survival (OS) was 36.4 vs 26.2 months (0.79; 0.57-1.08). In ENDEAVOR, median PFS was 18.7 (Kd56) vs 6.6 months (Vd) (0.50; 0.36-0.68); median OS was 33.6 vs 21.8 months (0.75; 0.56-1.00). In ARROW, median PFS was 10.3 (once-weekly Kd70) vs 6.6 months (twice-weekly Kd27) (0.76; 0.49-1.16). In all 3 studies, rates of grade ≥3 treatment-emergent adverse events were consistent with those observed in the primary studies. The ASPIRE, ENDEAVOR, and ARROW primary analyses demonstrated favorable benefit-risk profiles with carfilzomib-containing regimens compared with controls. Across clinically relevant subgroups, including those by frailty status, consistent efficacy and safety were observed with KRd27, Kd56, and weekly Kd70, and treatment with these regimens should not be restricted by frailty status.",
author = "Thierry Facon and Ruben Niesvizky and Maria-Victoria Mateos and David Siegel and Cara Rosenbaum and Sara Bringhen and Katja Weisel and Ho, {P Joy} and Heinz Ludwig and Shaji Kumar and Kenneth Wang and Mihaela Obreja and Zhao Yang and Zandra Klippel and Khalid Mezzi and Amanda Goldrick and Christina Tekle and Dimopoulos, {Meletios A}",
note = "{\textcopyright} 2020 by The American Society of Hematology.",
year = "2020",
month = nov,
day = "10",
doi = "10.1182/bloodadvances.2020001965",
language = "English",
volume = "4",
pages = "5449--5459",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "21",

}

RIS

TY - JOUR

T1 - Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

AU - Facon, Thierry

AU - Niesvizky, Ruben

AU - Mateos, Maria-Victoria

AU - Siegel, David

AU - Rosenbaum, Cara

AU - Bringhen, Sara

AU - Weisel, Katja

AU - Ho, P Joy

AU - Ludwig, Heinz

AU - Kumar, Shaji

AU - Wang, Kenneth

AU - Obreja, Mihaela

AU - Yang, Zhao

AU - Klippel, Zandra

AU - Mezzi, Khalid

AU - Goldrick, Amanda

AU - Tekle, Christina

AU - Dimopoulos, Meletios A

N1 - © 2020 by The American Society of Hematology.

PY - 2020/11/10

Y1 - 2020/11/10

N2 - Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance status or comorbidities. This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib [27 mg/m2]-lenalidomide-dexamethasone [KRd27] vs lenalidomide-dexamethasone [Rd]), ENDEAVOR (carfilzomib [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), and ARROW (once-weekly carfilzomib [70 mg/m2]-dexamethasone [Kd70] vs carfilzomib [27 mg/m2]-dexamethasone [Kd27]) studies. A frailty algorithm incorporating age, Charlson comorbidity index, and performance status classified patients as fit, intermediate, or frail. Results are presented for frail patients (ASPIRE, n = 196; ENDEAVOR, n = 330; ARROW, n = 141). In ASPIRE, median progression-free survival (PFS) (hazard ratio; 95% confidence interval) was 24.1 (KRd27) vs 15.9 months (Rd) (0.78; 0.54-1.12); median overall survival (OS) was 36.4 vs 26.2 months (0.79; 0.57-1.08). In ENDEAVOR, median PFS was 18.7 (Kd56) vs 6.6 months (Vd) (0.50; 0.36-0.68); median OS was 33.6 vs 21.8 months (0.75; 0.56-1.00). In ARROW, median PFS was 10.3 (once-weekly Kd70) vs 6.6 months (twice-weekly Kd27) (0.76; 0.49-1.16). In all 3 studies, rates of grade ≥3 treatment-emergent adverse events were consistent with those observed in the primary studies. The ASPIRE, ENDEAVOR, and ARROW primary analyses demonstrated favorable benefit-risk profiles with carfilzomib-containing regimens compared with controls. Across clinically relevant subgroups, including those by frailty status, consistent efficacy and safety were observed with KRd27, Kd56, and weekly Kd70, and treatment with these regimens should not be restricted by frailty status.

AB - Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance status or comorbidities. This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib [27 mg/m2]-lenalidomide-dexamethasone [KRd27] vs lenalidomide-dexamethasone [Rd]), ENDEAVOR (carfilzomib [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), and ARROW (once-weekly carfilzomib [70 mg/m2]-dexamethasone [Kd70] vs carfilzomib [27 mg/m2]-dexamethasone [Kd27]) studies. A frailty algorithm incorporating age, Charlson comorbidity index, and performance status classified patients as fit, intermediate, or frail. Results are presented for frail patients (ASPIRE, n = 196; ENDEAVOR, n = 330; ARROW, n = 141). In ASPIRE, median progression-free survival (PFS) (hazard ratio; 95% confidence interval) was 24.1 (KRd27) vs 15.9 months (Rd) (0.78; 0.54-1.12); median overall survival (OS) was 36.4 vs 26.2 months (0.79; 0.57-1.08). In ENDEAVOR, median PFS was 18.7 (Kd56) vs 6.6 months (Vd) (0.50; 0.36-0.68); median OS was 33.6 vs 21.8 months (0.75; 0.56-1.00). In ARROW, median PFS was 10.3 (once-weekly Kd70) vs 6.6 months (twice-weekly Kd27) (0.76; 0.49-1.16). In all 3 studies, rates of grade ≥3 treatment-emergent adverse events were consistent with those observed in the primary studies. The ASPIRE, ENDEAVOR, and ARROW primary analyses demonstrated favorable benefit-risk profiles with carfilzomib-containing regimens compared with controls. Across clinically relevant subgroups, including those by frailty status, consistent efficacy and safety were observed with KRd27, Kd56, and weekly Kd70, and treatment with these regimens should not be restricted by frailty status.

U2 - 10.1182/bloodadvances.2020001965

DO - 10.1182/bloodadvances.2020001965

M3 - SCORING: Journal article

C2 - 33166401

VL - 4

SP - 5449

EP - 5459

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 21

ER -